While recognizing that the bipartisan Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act is not a silver bullet that will bring down all drug prices, U.S. officials and several experts gave the bill high marks last week during a House Judiciary subcommittee on antitrust concerns and the FDA drug approval process.